https://efba.ae/blog/collagen-iv-therapy/ 2026-08-30 monthly 0.7 https://efba.ae/assets/img/blog/collagen-iv-therapy-cover.webp العلاج الوريدي بالكولاجين — لماذا لا يمكن تسريب لولب ثلاثي كتلته نحو 300 كيلودالتون، وما الذي يحويه تسريب الكولاجين فعلاً، وماذا وجدت التحاليل التلوية للببتيدات الفموية بعد فصل مصدر التمويل، والأدلة مصنّفةً بحسب الداعية والطريق https://efba.ae/en/blog/collagen-iv-therapy/ 2026-08-30 monthly 0.7 https://efba.ae/assets/img/blog/collagen-iv-therapy-cover.webp Collagen IV therapy — why a 300 kDa triple helix cannot be infused, what a collagen drip actually contains, what the oral peptide meta-analyses found once funding source was separated out, and the evidence graded by indication and route https://efba.ae/blog/biotin-iv-therapy/ 2026-08-23 monthly 0.7 https://efba.ae/assets/img/blog/biotin-iv-therapy-cover.webp العلاج الوريدي بالبيوتين — تفاعلات الكربوكسلة التي يخدمها، وبيانات التوافر الحيوي الفموي مقابل الوريدي، وما وجدته تجارب الشعر والأظافر، والتداخل مع المقايسات المناعية https://efba.ae/en/blog/biotin-iv-therapy/ 2026-08-23 monthly 0.7 https://efba.ae/assets/img/blog/biotin-iv-therapy-cover.webp Biotin IV therapy — the carboxylase reactions biotin serves, the oral versus intravenous bioavailability data, what the hair and nail trials found, and the immunoassay interference the FDA has warned about https://efba.ae/blog/l-carnitine-iv-therapy/ 2026-08-16 monthly 0.7 https://efba.ae/assets/img/blog/l-carnitine-iv-therapy-cover.webp العلاج الوريدي بإل-كارنيتين — مكّوك الكارنيتين وسقف التقاط العضلة وداعيتا العوز المسجَّلتان والأدلة مصنّفةً بحسب الداعية https://efba.ae/en/blog/l-carnitine-iv-therapy/ 2026-08-16 monthly 0.7 https://efba.ae/assets/img/blog/l-carnitine-iv-therapy-cover.webp L-carnitine IV therapy — the carnitine shuttle, the muscle uptake ceiling, the two licensed deficiency indications, and evidence graded by indication https://efba.ae/ monthly 1.0 https://efba.ae/en/ monthly 0.9 https://efba.ae/catalogue/ 2026-06-17 monthly 0.9 https://efba.ae/assets/img/products/ivixir-to-infinity-md.webp IVIXIR To Infinity MD — NAD+, carnosine and vitamin C anti-aging concept https://efba.ae/assets/img/products/ivixir-nad-300-md.webp IVIXIR NAD+ 300 MD — NAD+ cellular energy and longevity concept https://efba.ae/assets/img/products/ivixir-myersence-md.webp IVIXIR MyerSence MD — Myers' Cocktail micronutrient concept https://efba.ae/en/catalogue/ 2026-06-17 monthly 0.9 https://efba.ae/assets/img/products/ivixir-to-infinity-md.webp IVIXIR To Infinity MD — NAD+, carnosine and vitamin C anti-aging concept https://efba.ae/assets/img/products/ivixir-nad-300-md.webp IVIXIR NAD+ 300 MD — NAD+ cellular energy and longevity concept https://efba.ae/blog/ 2026-08-09 weekly 0.7 https://efba.ae/en/blog/ 2026-08-09 weekly 0.7 https://efba.ae/blog/magnesium-iv-therapy/ 2026-08-09 monthly 0.7 https://efba.ae/assets/img/blog/magnesium-iv-therapy-cover.webp Magnesium IV therapy — eclampsia and torsades indications, the asthma evidence split, and dosing and hypermagnesaemia limits https://efba.ae/en/blog/magnesium-iv-therapy/ 2026-08-09 monthly 0.7 https://efba.ae/assets/img/blog/magnesium-iv-therapy-cover.webp Magnesium IV therapy — eclampsia and torsades indications, the asthma evidence split, and dosing and hypermagnesaemia limits https://efba.ae/blog/amino-acid-iv-therapy/ 2026-08-03 monthly 0.7 https://efba.ae/assets/img/blog/amino-acid-iv-therapy-cover.webp Amino acid IV therapy — glutamine critical-care harm signal, PROTECTION kidney-protection trial, and evidence-graded dosing by molecule https://efba.ae/en/blog/amino-acid-iv-therapy/ 2026-08-03 monthly 0.7 https://efba.ae/assets/img/blog/amino-acid-iv-therapy-cover.webp Amino acid IV therapy — glutamine critical-care harm signal, PROTECTION kidney-protection trial, and evidence-graded dosing by molecule https://efba.ae/blog/b12-folate-methylation-iv-therapy/ 2026-07-27 monthly 0.7 https://efba.ae/assets/img/blog/b12-folate-methylation-iv-therapy-cover.webp Vitamin B12 and folate IV therapy — methylation cycle, route of administration, homocysteine outcome trials and evidence-graded dosing https://efba.ae/en/blog/b12-folate-methylation-iv-therapy/ 2026-07-27 monthly 0.7 https://efba.ae/assets/img/blog/b12-folate-methylation-iv-therapy-cover.webp Vitamin B12 and folate IV therapy — methylation cycle, route of administration, homocysteine outcome trials and evidence-graded dosing https://efba.ae/blog/alpha-lipoic-acid-iv-therapy/ 2026-07-19 monthly 0.7 https://efba.ae/assets/img/blog/alpha-lipoic-acid-iv-therapy-cover.webp Alpha-lipoic acid IV therapy — mechanism, decades of diabetic neuropathy trial evidence and dosing for intravenous ALA infusion https://efba.ae/en/blog/alpha-lipoic-acid-iv-therapy/ 2026-07-19 monthly 0.7 https://efba.ae/assets/img/blog/alpha-lipoic-acid-iv-therapy-cover.webp Alpha-lipoic acid IV therapy — mechanism, decades of diabetic neuropathy trial evidence and dosing for intravenous ALA infusion https://efba.ae/blog/nad-iv-therapy/ 2026-07-12 monthly 0.7 https://efba.ae/assets/img/blog/nad-iv-therapy-cover.webp NAD+ IV therapy — mechanism, the 2024 head-to-head trial and dosing for intravenous NAD+ infusion https://efba.ae/en/blog/nad-iv-therapy/ 2026-07-12 monthly 0.7 https://efba.ae/assets/img/blog/nad-iv-therapy-cover.webp NAD+ IV therapy — mechanism, the 2024 head-to-head trial and dosing for intravenous NAD+ infusion https://efba.ae/blog/vitamin-c-iv-therapy/ 2026-07-05 monthly 0.7 https://efba.ae/assets/img/blog/vitamin-c-iv-therapy-cover.webp High-dose IV vitamin C — mechanism, clinical evidence and dosing for ascorbate infusion https://efba.ae/en/blog/vitamin-c-iv-therapy/ 2026-07-05 monthly 0.7 https://efba.ae/assets/img/blog/vitamin-c-iv-therapy-cover.webp High-dose IV vitamin C — mechanism, clinical evidence and dosing for ascorbate infusion https://efba.ae/blog/glutathione-iv-therapy/ 2026-06-29 monthly 0.7 https://efba.ae/assets/img/blog/glutathione-iv-therapy-cover.webp Glutathione IV therapy — mechanism, clinical evidence and dosing for the body's master antioxidant https://efba.ae/en/blog/glutathione-iv-therapy/ 2026-06-29 monthly 0.7 https://efba.ae/assets/img/blog/glutathione-iv-therapy-cover.webp Glutathione IV therapy — mechanism, clinical evidence and dosing for the body's master antioxidant https://efba.ae/blog/myers-cocktail-iv-therapy/ 2026-06-22 monthly 0.7 https://efba.ae/assets/img/blog/myers-cocktail-iv-therapy-cover.webp Myers' cocktail — ingredients, doses and evidence for IV micronutrient therapy https://efba.ae/en/blog/myers-cocktail-iv-therapy/ 2026-06-22 monthly 0.7 https://efba.ae/assets/img/blog/myers-cocktail-iv-therapy-cover.webp Myers' cocktail — ingredients, doses and evidence for IV micronutrient therapy https://efba.ae/blog/nad-vs-nmn-longevity/ 2026-06-18 monthly 0.6 https://efba.ae/assets/img/blog/nad-vs-nmn-longevity-cover.webp NAD+ vs NMN — an evidence-based comparison for longevity practice https://efba.ae/en/blog/nad-vs-nmn-longevity/ 2026-06-18 monthly 0.6 https://efba.ae/assets/img/blog/nad-vs-nmn-longevity-cover.webp NAD+ vs NMN — an evidence-based comparison for longevity practice https://efba.ae/legal/legal-notice.html yearly 0.3 https://efba.ae/legal/privacy-policy.html yearly 0.3 https://efba.ae/legal/terms.html yearly 0.3